West Pharmaceutical Services (NYSE:WST) Releases FY 2024 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 6.350-6.650 for the period, compared to the consensus estimate of 7.740. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Stock Performance

WST stock traded down $46.61 during mid-day trading on Thursday, reaching $277.16. The company had a trading volume of 3,347,337 shares, compared to its average volume of 559,091. West Pharmaceutical Services has a one year low of $265.00 and a one year high of $415.73. The stock has a market capitalization of $20.19 billion, a P/E ratio of 36.56, a P/E/G ratio of 5.61 and a beta of 1.00. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03. The stock’s 50-day simple moving average is $325.51 and its two-hundred day simple moving average is $356.21.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.27. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The firm had revenue of $695.40 million for the quarter, compared to the consensus estimate of $670.62 million. During the same period last year, the firm posted $1.98 EPS. West Pharmaceutical Services’s quarterly revenue was down 3.0% compared to the same quarter last year. Research analysts anticipate that West Pharmaceutical Services will post 7.76 EPS for the current year.

Insider Activity

In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Silji Abraham sold 1,800 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the sale, the chief executive officer now owns 152,908 shares in the company, valued at $56,063,718.20. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.